Understanding cancers linked to Epstein-Barr Virus
Official title: Models of EBV Cancer
Funded at Wistar Institute · NIH-11085175 · Data updated 2026-11-12
This study is exploring new ways to understand and treat cancers linked to the Epstein-Barr Virus, like nasopharyngeal and gastric cancers, by using special lab techniques that mimic real tumors, so we can find better treatments for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $302,036 |
| NIH project number | 5P01CA269043-03 |
| Project ID | NIH-11085175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with nasopharyngeal or gastric cancers linked to Epstein-Barr Virus.
✕Less likely to help
Patients with cancers not associated with Epstein-Barr Virus may not receive any benefit from this research.
What this research studies
This research focuses on developing and utilizing advanced models to study cancers associated with the Epstein-Barr Virus (EBV), particularly nasopharyngeal and gastric cancers. It employs innovative techniques such as organoid cultures, which closely mimic the tumor environment, and patient-derived xenografts to test potential treatments. The research aims to identify viral and cellular factors that contribute to these cancers and evaluate new therapeutic compounds. By leveraging a large repository of cancer cell lines and organoid cultures, the project seeks to enhance our understanding of EBV-related cancers and improve treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with EBV-associated cancers.
How similar studies have gone: Previous research has shown promise in using organoid cultures and patient-derived models to study cancer, indicating a strong potential for success in this approach.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Soldan, Samantha Standish — Wistar Institute
- Study coordinator: Soldan, Samantha Standish
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.